<script>
	import { TopNav, Footer } from '$lib/components/index';
	import Content from './index.md';
</script>

<TopNav />

<div class="prose-lg mx-auto max-w-4xl p-8 dark:prose-invert md:p-20">
	<Content />
</div>

<Footer>
	<p>
		[1]: Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as
		Needed for Mild Asthma. N Engl J Med. 2019;380(21):2020-2030. doi:10.1056/NEJMoa1901963
	</p>

	<p>
		[2]: O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide–Formoterol as
		Needed in Mild Asthma. _New England Journal of Medicine_. 2018;378(20):1865-1876.
		doi:[10.1056/NEJMoa1715274](https://doi.org/10.1056/NEJMoa1715274)
	</p>

	<p>
		[3]: Singh D, Agusti A, Martinez FJ, et al. Blood Eosinophils and Chronic Obstructive Pulmonary
		Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review.
		Am J Respir Crit Care Med 2022; 206(1): 17-24.
	</p>

	<p>
		[4]: Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive
		pulmonary disease. Cochrane Database Syst Rev 2012; 7(7): CD002991.
	</p>

	<p>
		[5]: Pocket Guide for Asthma Management and Prevention. Global Initiative for Asthma - GINA.
		Accessed June 17, 2023. https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/
	</p>

	<p>
		[6]: Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA Therapy
		versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review
		and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. Ann
		Am Thorac Soc. 2020;17(9):1133-1143. doi:10.1513/AnnalsATS.201912-915OC
	</p>
</Footer>
